Analyst David Risinger of Leerink Partners maintained a Buy rating on Centessa Pharmaceuticals (CNTA – Research Report), boosting the price target to $36.00.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
David Risinger has given his Buy rating due to a combination of factors, primarily centered around Centessa Pharmaceuticals’ promising orexin portfolio. The company is targeting substantial markets for hypersomnia and excessive daytime sleepiness, with their orexin 2 receptor showing best-in-class potency and selectivity. Risinger increased the odds of success for their ORX-750 program, reflecting confidence in its market potential, and adjusted the 2032 sales estimates significantly higher than consensus expectations.
Furthermore, the potential for additional upside is notable, as future sales projections for other orexin candidates targeting larger markets have not yet been incorporated. The upcoming data presentations and the transformational potential of orexin agonists in sleep-wake disorders further support the Buy rating. These factors collectively suggest that Centessa Pharmaceuticals’ stock presents a compelling investment opportunity with significant upside potential.
Risinger covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Bristol-Myers Squibb, and Vertex Pharmaceuticals. According to TipRanks, Risinger has an average return of 10.6% and a 56.89% success rate on recommended stocks.
In another report released on March 7, Morgan Stanley also initiated coverage with a Buy rating on the stock with a $27.00 price target.